

Franck Morceau

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11967466/publications.pdf>

Version: 2024-02-01

31
papers

2,313
citations

304743

22
h-index

434195

31
g-index

31
all docs

31
docs citations

31
times ranked

3852
citing authors

#	ARTICLE	IF	CITATIONS
1	Spingolipid-mediated inflammatory signaling leading to autophagy inhibition converts erythropoiesis to myelopoiesis in human hematopoietic stem/progenitor cells. <i>Cell Death and Differentiation</i> , 2019, 26, 1796-1812.	11.2	56
2	Natural compounds and pharmaceuticals reprogram leukemia cell differentiation pathways. <i>Biotechnology Advances</i> , 2015, 33, 785-797.	11.7	30
3	Valproic acid regulates erythro-megakaryocytic differentiation through the modulation of transcription factors and microRNA regulatory micro-networks. <i>Biochemical Pharmacology</i> , 2014, 92, 299-311.	4.4	17
4	Polyphenol tri-vanillic ester 13c inhibits P-JAK2V617F and Bcrâ€“Abl oncokinese expression in correlation with STAT3/STAT5 inactivation and apoptosis induction in human leukemia cells. <i>Cancer Letters</i> , 2013, 340, 30-42.	7.2	6
5	Long and Short Non-Coding RNAs as Regulators of Hematopoietic Differentiation. <i>International Journal of Molecular Sciences</i> , 2013, 14, 14744-14770.	4.1	58
6	Dietary compounds as potent inhibitors of the signal transducers and activators of transcription (STAT) 3 regulatory network. <i>Genes and Nutrition</i> , 2012, 7, 111-125.	2.5	28
7	UNBS1450, a steroid cardiac glycoside inducing apoptotic cell death in human leukemia cells. <i>Biochemical Pharmacology</i> , 2011, 81, 13-23.	4.4	86
8	Valproic acid perturbs hematopoietic homeostasis by inhibition of erythroid differentiation and activation of the myelo-monocytic pathway. <i>Biochemical Pharmacology</i> , 2011, 81, 498-509.	4.4	34
9	Tumor necrosis factor alpha-mediated inhibition of erythropoiesis involves GATA-1/GATA-2 balance impairment and PU.1 over-expression. <i>Biochemical Pharmacology</i> , 2011, 82, 156-166.	4.4	40
10	Heteronemin, a spongean sesterterpene, inhibits TNFÎ±-induced NF-Î±B activation through proteasome inhibition and induces apoptotic cell death. <i>Biochemical Pharmacology</i> , 2010, 79, 610-622.	4.4	85
11	Molecular and Therapeutic Potential and Toxicity of Valproic Acid. <i>Journal of Biomedicine and Biotechnology</i> , 2010, 2010, 1-18.	3.0	347
12	Oxidative, multistep activation of the noncanonical NF-Î±B pathway <i>via</i> disulfide Bclâ€“3/p50 complex. <i>FASEB Journal</i> , 2009, 23, 45-57.	0.5	29
13	Linking anemia to inflammation and cancer: The crucial role of TNFÎ±. <i>Biochemical Pharmacology</i> , 2009, 77, 1572-1579.	4.4	57
14	The inhibitory effect of the proinflammatory cytokine TNFÎ± on erythroid differentiation involves erythroid transcription factor modulation. <i>International Journal of Oncology</i> , 2009, 34, 853-60.	3.3	10
15	Radicicolâ€“mediated inhibition of Bcrâ€“Ab1 in K562 cells induced p38â€“MAPK dependent erythroid differentiation and PU.1 downâ€“regulation. <i>BioFactors</i> , 2008, 34, 313-329.	5.4	13
16	Tumor necrosis factor Î± inhibits erythroid differentiation in human erythropoietin-dependent cells involving p38 MAPK pathway, GATA-1 and FOG-1 downregulation and GATA-2 upregulation. <i>Biochemical Pharmacology</i> , 2008, 76, 1229-1239.	4.4	53
17	Tumor necrosis factor alpha inhibits aclacinomycin A-induced erythroid differentiation of K562 cells via GATA-1. <i>Cancer Letters</i> , 2006, 240, 203-212.	7.2	17
18	Transcriptional and post-transcriptional regulation of glutathione S-transferase P1 expression during butyric acid-induced differentiation of K562 cells. <i>Leukemia Research</i> , 2006, 30, 561-568.	0.8	16

#	ARTICLE	IF	CITATIONS
19	Inhibition of TNF α -induced activation of nuclear factor κ B by kava (Piper methysticum) derivatives. <i>Biochemical Pharmacology</i> , 2006, 71, 1206-1218.	4.4	83
20	Chemopreventive and therapeutic effects of curcumin. <i>Cancer Letters</i> , 2005, 223, 181-190.	7.2	771
21	Regulation of glutathione S-transferase P1-1 gene expression by NF-kappaB in tumor necrosis factor alpha-treated K562 leukemia cells. <i>Biochemical Pharmacology</i> , 2004, 67, 1227-1238.	4.4	44
22	Increased glutathione S-transferase P1-1 expression by mRNA stabilization in hemin-induced differentiation of K562 cells. <i>Biochemical Pharmacology</i> , 2004, 68, 1269-1277.	4.4	20
23	Effect of chemopreventive agents on glutathione S-transferase P1-1 gene expression mechanisms via activating protein 1 and nuclear factor kappaB inhibition. <i>Biochemical Pharmacology</i> , 2004, 68, 1101-1111.	4.4	75
24	Curcumin Stability and Its Effect on GlutathioneS-Transferase P1-1 mRNA Expression in K562 Cells. <i>Annals of the New York Academy of Sciences</i> , 2004, 1030, 442-448.	3.8	25
25	GATA α 1: Friends, Brothers, and Coworkers. <i>Annals of the New York Academy of Sciences</i> , 2004, 1030, 537-554.	3.8	56
26	Expression of glutathione S-transferase P1-1 in leukemic cells is regulated by inducible AP-1 binding. <i>Cancer Letters</i> , 2004, 216, 207-219.	7.2	36
27	Induction of apoptosis by curcumin: mediation by glutathione S-transferase P1-1 inhibition. <i>Biochemical Pharmacology</i> , 2003, 66, 1475-1483.	4.4	124
28	Expression of glutathione S-transferase P1-1 in differentiating K562: role of GATA-1. <i>Biochemical and Biophysical Research Communications</i> , 2003, 311, 815-821.	2.1	16
29	Phorbol ester responsiveness of the glutathione S-transferase P1 gene promoter involves an inducible c-jun binding in human K562 leukemia cells. <i>Leukemia Research</i> , 2001, 25, 241-247.	0.8	23
30	Regulation of transcription of the glutathione S-transferase P1 gene by methylation of the minimal promoter in human leukemia cells. <i>Biochemical Pharmacology</i> , 2001, 61, 605-612.	4.4	24
31	Evidence for distinct regulation processes in the aclacinomycin- and doxorubicin-mediated differentiation of human erythroleukemic cells. <i>Biochemical Pharmacology</i> , 1996, 51, 839-845.	4.4	34